Ixabepilone - R Pharm
Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; IXEMPRA; Ixempra; NSC 710428; Patupilone analogueLatest Information Update: 29 Nov 2023
At a glance
- Originator GBF
- Developer Allarity Therapeutics; Bristol-Myers Squibb; R-Pharm; Yale University
- Class Antineoplastics; Epothilones; Macrolides; Small molecules
- Mechanism of Action Cell cycle inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
- Discontinued Cancer; Endometrial cancer; Prostate cancer
Most Recent Events
- 21 Nov 2023 R-Pharma in collaboration with Yale university completes a phase-II clinical trial in Ovarian cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer (In the elderly, Metastatic disease, Second-line therapy or greater, In adults, Combination therapy) in USA (IV) (NCT03093155)
- 05 Jul 2023 Efficacy data from a phase II trial in Breast cancer released by Allarity Therapeutics
- 22 Dec 2021 Vector Pharma and R-PHARM enter into a licensing agreement to market ixabepilone for Breast cancer in Morocco, Tunisia, Algeria, Libya, Egypt, Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Lebanon, Jordan, and Iraq